| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7687516 | CIPLA | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
| US7589106 | CIPLA | Alcohol free formulation of argatroban |
Sep, 2027
(3 years from now) | |
Argatroban In Sodium Chloride is owned by Cipla.
Argatroban In Sodium Chloride contains Argatroban.
Argatroban In Sodium Chloride has a total of 2 drug patents out of which 0 drug patents have expired.
Argatroban In Sodium Chloride was authorised for market use on 29 June, 2011.
Argatroban In Sodium Chloride is available in injectable;intravenous dosage forms.
Argatroban In Sodium Chloride can be used as method of treating thrombosis, method of treating an argatroban treatable condition.
The generics of Argatroban In Sodium Chloride are possible to be released after 26 September, 2027.
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis
Dosage: INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE family patents
